Doberstein fills newly created position at Nektar
Nektar Therapeutics has appointed Stephen Doberstein as senior vice president and chief scientific officer.
Doberstein brings more than 17 years of experience in biotechnology research and development to the company and in this newly created role will lead all aspects of discovery research.
Prior to joining Nektar, Doberstein was vice president of research at Xoma. He has also held this role at Five Prime Therapeutics and Xencor. He also held a number of senior positions at Exelixis.